Performance of Crohn’s disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data | Zendy

Brian G. Feagan | Zendy; William J. Sandborn | Zendy; Paul Rutgeerts | Zendy; Barrett G. Levesque | Zendy; Reena Khanna | Zendy; Bidan Huang | Zendy; Qian Zhou | Zendy; JenFue Maa | Zendy; Kori Wallace | Zendy; Ana P. Lacerda | Zendy; Roopal Thakkar | Zendy; Anne Robinson | Zendy

Open Access

Performance of Crohn’s disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data

Author(s) -

Brian G. Feagan,

William J. Sandborn,

Paul Rutgeerts,

Barrett G. Levesque,

Reena Khanna,

Bidan Huang,

Qian Zhou,

JenFue Maa,

Kori Wallace,

Ana P. Lacerda,

Roopal Thakkar,

Anne Robinson

Publication year - 2018

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izx082

Subject(s) - medicine , clinical endpoint , adalimumab , placebo , crohn's disease , clinical trial , post hoc analysis , colonoscopy , randomized controlled trial , inflammatory bowel disease , endoscopy , gastroenterology , disease , pathology , colorectal cancer , alternative medicine , cancer

Clinical trial endpoints for Crohn's disease (CD) activity correlate poorly with mucosal inflammation; to assess treatment efficacy, patient-reported outcomes and endoscopic assessments are preferred. This study assessed the impact on treatment efficacy estimations of using different definitions of clinical and endoscopic remission and endoscopic response, and of using site- or central-based endoscopy evaluation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research